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Abstract
The prenatal diagnosis of congenital toxoplasmosis is currently based upon molecular biology using a sample of amniotic ﬂuid. The vast
majority of centres globally (and all centres in France) performing this diagnosis use ‘in house’ or laboratory-developed PCR assays. This
may be the source of considerable inter-laboratory variation in the performances of the assays, hampering any valuable comparison of data
among different centres. The present study was based upon questionnaires that were sent to 21–25 centres between 2002 and 2005
enquiring about methods and practices of the PCR-based prenatal diagnosis of congenital toxoplasmosis. An extreme diversity of PCR
methods and practices was observed. Thus, in 2005, 35 PCR methods, differing in one of the main steps of the whole process, were
reported as being in use for routine diagnosis, with nine centres using two or three methods. We provide comprehensive information on
the extraction methods, DNA targets, primer pairs and detection methods used for this diagnosis, as well as their evolution, during the per-
iod of study. Interestingly, in this period (2002–2005), a rapid progression of the number of laboratories using real-time PCR technology,
which increased from four to 19, was observed. We also studied general PCR practices concerning, for example, the number of reaction
tubes used for each biological sample and the inclusion of controls. The return of information in a yearly report provided the opportunity
for writing proposals aiming to improve laboratory practices for this diagnosis at the national level. The high diversity of methods and prac-
tices currently used emphasizes the need for external quality assessment of the performances of the molecular diagnostic methods.
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Introduction
Toxoplasmosis is an endemic protozoan disease whose prime
public health importance is the result of possible vertical
transmission from an infected mother to her foetus during
pregnancy. Prenatal diagnosis (PND) of congenital toxoplas-
mosis (CT), wherever it has been implemented, has consider-
ably improved the prognosis and outcome of infected
children. Prevention of CT, including PND, has become a
national policy in France ever since 1978 [1]. This national
policy requires: (i) the detection and follow-up of non-immu-
nized women as soon as possible during pregnancy with a
series of serological tests; (ii) appropriate counselling aiming
at limiting the risks of contamination; (iii) the detection and
treatment of toxoplasmosis as early as possible aiming to
prevent or limit transmission to the foetus and its conse-
quences; (iv) PND of CT associated with monthly ultrasound
examinations in case of a seroconversion; (v) combined
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sulfadiazine-pyrimethamine treatment during pregnancy if CT
is detected; and (vi) clinical, radiological and serological
surveillance of neonates and infants at risk. This prevention
programme is justiﬁed by the high prevalence of acquired
toxoplasmosis in adults in France (approximately 44%) [2]
and by the estimated yearly incidence of contamination in
women during pregnancy (six or seven per 1000) and of con-
genital toxoplasmosis (approximately 0.1% of births) [3]. The
programme was recently reinforced by the creation of a
National Reference Centre for Toxoplasmosis (http://
www.chu-reims.fr/professionnels/cnr-toxoplasmose-1/) which
includes a ‘pole’ of molecular biology whose objectives
include the improvement and standardization of the molecu-
lar diagnosis of CT, and whose coordinator is one of us (PB).
Indeed, molecular diagnostic tests, based upon PCR using
amniotic ﬂuid, have become essential in the diagnosis of CT;
they have in great part superseded more classical methods,
and have also led to the elimination of the need for cordo-
centesis [4]. In France, the PND of CT is made essentially in
university hospitals, as well as in two large private biological
diagnosis centres. Not all university hospital centres perform
such testing because the centres and practitioners concerned
need ofﬁcial authorization from the national health authori-
ties to estabish this diagnosis, which is granted for 5 years.
However, despite their wide use, all PCR assays used for
this application are still ‘in-house’- or laboratory-developed
methods (i.e. they have been set up independently in each
laboratory using different targets and customized primers and
reaction conditions). In addition, ‘in-house’ methods can
largely differ at any step during the diagnostic process, such
as the extraction method, the number of PCR tubes used for
diagnosis, the inclusion of an internal control for the detec-
tion of inhibitors of the reaction, etc. These differences may
be a source of considerable inter-laboratory variation in the
performances of the assays, inﬂuencing the quality of the diag-
nosis and hampering any valuable comparison of data among
centres. Previous studies have highlighted the lack of homoge-
neity and performance in European countries and underlined
the need for guidelines [5,6]. In view of this heterogeneity,
standardization of PCR methods and practices has become a
strong desire for both health authorities and the community
of clinical microbiologists. Such a standardization should in
turn lead to improvement of the diagnosis of CT at a more
global level, particularly regarding sensitivity, because parasite
loads in this afﬂiction are often very low [7].
To implement the harmonization of PND of CT in France,
an early initiative for quality assurance in the molecular PND
of toxoplasmosis was launched by the French association of
hospital practitioners and teachers in Parasitology-Mycology
(ANOFEL) in 2002. Brieﬂy, a panel of Toxoplasma gondii-posi-
tive and -negative amniotic ﬂuid samples prepared in Mont-
pellier was sent blinded to participating centres for PCR
testing on a yearly basis, allowing each centre to assess and
follow its own performances in the molecular detection of
CT [8].
A national survey was conducted in parallel from 2002 to
2005 aiming to assess the diversity and evolution of methods
and practices used in this molecular diagnosis in France. The
survey focused exclusively on the molecular PND of CT.
The analysis of the data reported here provides an almost
comprehensive description of these activities in France dur-
ing the study period. It revealed a surprisingly high degree of
diversity and the absence of any spontaneous trend toward
standardization. Also, a massive introduction of quantitative
‘real-time’ PCR (qrtPCR) technology was observed during
the study period, as opposed to ‘conventional’ PCR (cnPCR),
a term used here for any form of end-point detection.
Materials and Methods
All laboratories of Parasitology–Mycology belonging to uni-
versity hospitals, as well as one of the two ofﬁcially autho-
rized private diagnosis centres, were informed of the yearly
external quality assessment (EQA) described previously [8].
Participating laboratories were free to enroll, anonymity of
results was guaranteed, and no fees were imposed for partic-
ipation. A questionnaire was sent every year to each partici-
pant, together with the EQA panel.
Participation in the EQA was anonymized through the use
of letter codes and double-blinded cross-reading between
the laboratories in Montpellier and Nice. An analysis of the
questionnaires was performed after transcription of the data
into spreadsheet software. The questionnaires included 11
queries concerning what we considered to be the most criti-
cal points of the PCR process. The query items are
described below in the Results section. All answers to que-
ries had to be given considering the routine practice of PND
of CT, and not the procedures that could have been per-
formed for the EQA only.
Results and Discussion
General observations
Between 2002 and 2005, the number of centres participating
in the PND of CT increased from 21 to 25. All participants
were from French University hospitals; none of the two pri-
vate centres accredited for this diagnosis was involved. Most
participants (23/25, i.e. 92% in 2005) were ofﬁcially authorized
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to establish this diagnosis; this represented 100% and 92% of
the public centres and of all centres, respectively, that had
received ofﬁcial authorization to establish this PND. Unautho-
rized laboratories about to request authorization to establish
PND of CT were also accepted to perform the EQA and
participated in the enquiry.
All questionnaires were returned; only a few queries were
not answered by some laboratories. In all, 988 answers vs.
an expected total number of 1001 answers could be analy-
sed. Hence, the enquiry was highly representative of the
national practices of PND of CT during the study period.
During this period, the number of molecular diagnostic
methods used in routine practice increased from 28 to 35.
Indeed, some laboratories used more than one method for
routine diagnosis (Fig. 1). Different methods were deﬁned
here as differing by a major step of the diagnostic process,
such as the DNA extraction method, or with respect to
DNA primers or DNA target and type of PCR technology.
Use of a second molecular diagnostic method
Out of ten (40%) of the participating centres, nine used
routinely two and one used three variant methods in paral-
lel at one stage during the study period (Fig. 1). These vari-
ations concerned any of the major steps of the molecular
diagnostic method deﬁned above. A fundamental distinction
should be made here between the centres using two vari-
ant methods during a transitory switch period (usually
<1 year) and those deliberately choosing to use two meth-
ods. The latter represented about 30% of the total number
of laboratories.
The interest and rationale behind such a practice are dis-
cussed in the Supporting Information (Data S1).
Type of PCR technology and amplicon detection method
Our data show the considerable progression of real-time
PCR technologies over the study period (Fig. 1 and Table 1).
During these 4 years, the number of laboratories using
qrtPCR increased from four out of 21 to 19 out of 25
(19–76%) and the number of methods based on qrtPCR
increased from four out of 28 to 25 out of 35 (14–71%).
Among the 19 centres that used cnPCR in 2002, 13 had
changed for qrtPCR in 2005; nine laboratories still used
cnPCR in 2005, among which three also used a qrtPCR
method. The four centres that used qrtPCR in 2002 still
used it in 2005, and the four centres that joined the network
during the study period used qrtPCR technology. These data
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FIG. 1. Evolution of the number of methods used for molecular pre-
natal diagnosis of congenital toxoplasmosis between 2002 and 2005
in France. Closed squares indicate the total number of methods and
centres; the number of centres is indicated in brackets. Closed dia-
monds and closed triangles indicate the number of cnPCR and
qrtPCR methods, respectively. Histograms show the number of cen-
tres that used one method (bottom, white area) and two or three
methods (top, hatched area); the corresponding ﬁgures are indicated
within the histogram; only one laboratory used three methods in
2003 and 2005. Different methods were deﬁned as differing by one
of the main steps of the process (DNA extraction method, DNA
targets/primers or type of PCR technology).
TABLE 1. Diversity and evolution of PCR technology and
amplicon detection methods used for molecular prenatal
diagnosis of congenital toxoplasmosis between 2002 and
2005a
2002 2003 2004 2005
cnPCR 24 (19) 19 (15) 16 (12) 10 (9)
Ethidium bromide staining 21 (16) 18 (13) 16 (12) 10 (8)
PCR-ELISAb 6 (6) 4 (4) 3 (3) 2 (2)
Southern blot or sequencingc 3 (2) 4 (2) 4 (2) 0
qrtPCRd 4 (4) 10 (8) 15 (13) 25 (19)
Roche 1 (1) 5 (4) 7 (6) 15 (11)
SybrGreen 0 1(1) 0 3 (2)
Fluorescent probese 1 (1) 4 (3) 7 (6) 12 (9)
Applied 2 (2) 3 (2) 5 (4) 5 (4)
Fluorescent probese
Bio-Rad 1 (1) 1 (1) 1 (1) 3 (2)
Fluorescent probese
Rotorgene 2000 0 1 (1) 1 (1) 1 (1)
Fluorescent probese
Stratagene MX400 0 0 1 (1) 1 (1)
Fluorescent probese
Total 28 (21f) 29 (22f) 31 (23f) 35 (25f)
aThe number of methods is given preceding the number of centres (in parenthe-
sis) that use the particular method.
bPCR-ELISA was used as the sole detection method in 2002 and 2003 by,
respectively, three centres and one centre; otherwise, it was used in association
with ethidium bromide staining of agarose gels.
cBoth used in complement to ethidium bromide-stained gels. Sequencing was
used by one centre only in 2003 and 2004.
dRoche (Meylan, France): Light-Cycler 1.0, 2.0 and 480; Applied (Courta-
boeuf, France): ABI Prism 7000 and 7700, Bio-Rad (Marnes-la-Coquette,
France): one iQ and one iCycler.
eThe type of ﬂuorescent probes used (FRET, Taqman, etc.) could not be speci-
ﬁed in this study.
fThe sum of numbers of centres using ‘conventional’ PCR (cnPCR) and quantita-
tive ‘real-time’ PCR (qrtPCR) does not account for the total because one or
two centres used both technologies
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indicate that the change to qrtPCR reﬂects an inevitable
trend, which, we believe, is desirable. It is noteworthy that
the advent of this new technology did not reduce the heter-
ogeneity of the methods used at the national level as a result
(among other factors) of the diversity of the real-time PCR
equipment used, as well as of the methods of detection of
ampliﬁed DNA (Table 1).
Regarding for the amplicon detection method, most
cnPCRs were used with subsequent ethidium bromide-
stained agarose gels and only few used PCR-ELISA (Table 1;
see also Supporting Information, Data S2). For qrtPCR, spe-
ciﬁc ﬂuorescent oligo-probes were used instead of Sybr-
Green in all centres but one in 2003 and two in 2005
(Table 1). The interest of these different methods is dis-
cussed in the Supporting Information (Data S2).
Finally, it is noteworthy that, as opposed to the situation
in other countries [6], nested PCR was not in use in routine
practice in France during the study period, probably because
of the high contamination risks that are typically associated
with this type of PCR.
DNA extraction methods
Regarding DNA extraction, a minority of laboratories (7/21
in 2002 to 4/25 in 2005) preferred ‘laboratory-developed’
methods, including Tween-Nonidet-NaOH (TNN) and Che-
lex resin, to commercialized kits (Table 2). TNN comprises
a simple, inexpensive and highly efﬁcient DNA isolation
method ﬁrst described in 1994 [9]; its main drawback is that
it is not standardized; also of note is that it is not applicable
to blood-containing samples. The Chelex resin method was
rapidly abandoned, probably because of its well-known low
capacity for removing PCR inhibitors. Commercialized kits
from as many as six different manufacturers were used. Qia-
gen products were by far the most frequently used, although
it is not known whether this was based on scientiﬁc grounds
or a result of the better commercial strategy of this supplier.
What is needed to allow the microbiologist to make evi-
dence-based choices in this respect are comparative studies
of the extraction methods; however, few such studies are
available because they imply particularly complex and highly
standardized protocols [10].
Only one centre used two extraction methods (TNN and
a commercial kit) for a single PCR assay during the whole
period; the logic behind this practice was to ensure a better
quality of diagnosis in case of a fault in the DNA extraction.
DNA target and PCR primers
The diversity observed among the participating centres was
extremely high, with 17 primer pairs targeting four DNA
sequences (Table 3). The B1 gene [11] remained the most
popular target over the 4 years. However, we observed a
rapid increase in the use of the noncoding repetitive
sequence described by Homan et al. [12] that we termed
rep529. This may be related to the improved sensitivity com-
pared to that obtained with the B1 gene, as reported by sev-
eral authors [12–14]. The use of rRNA gene sequences [15]
decreased over the 4 years; and TGR1E, another repetitive
element described by Cristina et al. [16,17], was rapidly
abandoned.
Primers are generally chosen using software according to
speciﬁc criteria. The profusion of primer sets designed here
for the two major DNA targets cannot be justiﬁed on scien-
tiﬁc grounds but rather on personal preferences. In 2002, 12
different primer pairs were being used for four DNA targets,
and as many as 15 were used for three targets in 2005 [11–
15,17–24] (Table 3). For the B1 gene alone, nine different
primer pairs were used in 2002 and eight in 2005. At the
same time, the number of primer sets designed for rep529
(particularly for qrtPCR) increased from one to six, two of
them yet unpublished (Table 3; see also Supporting Informa-
tion, Fig. S1 and Table S1). Several of these primer pairs
TABLE 2. Diversity and evolution of DNA extraction meth-
ods used for the molecular prenatal diagnosis of congenital
toxoplasmosisa
2002 2003 2004 2005
Laboratory- developedb 7 (7) 6 (6) 5 (5) 4 (4)
Tween-Nonidet-NaOH 6 (6) 5 (5) 5 (5) 4 (4)
cnPCR 6 (6) 4 (4) 4 (4) 3 (3)
qrtPCR 0 1 (1) 1 (1) 1 (1)
Chelex 1 (1) 1(1) 0 0
cnPCR
Commercial kitsc 21 (15) 23 (17) 26 (19) 31 (22)
Qiagen 17 (12) 17 (13) 20 (15) 21 (16)
cnPCR 14 (11) 11 (9) 10 (8) 5 (4)
qrtPCR 3 (3) 6 (5) 10 (9) 16 (14)
GeneReleaser 1 (1) 1 (1) 0 0
qrtPCR
Epicentre 2 (1) 2 (1) 2 (1) 2 (1)
qrtPCR
Roche 1 (1) 3 (2) 4 (3) 4 (3)
qrtPCR
Magnapure 0 0 0 2 (2)
qrtPCR
QbioRobot 0 0 0 2 (1)
qrtPCR
Total 28 (21d) 29 (22d) 31 (23d) 35 (25d)
cnPCR 24 (19) 19 (15) 16 (12) 10 (8)
qrtPCR 4 (4) 10 (8) 15 (13) 25 (19)
aThe number of methods is given preceding the number of centres (in parenthe-
sis) that use the particular method.
bTNN, Tween-Nonidet-NaOH [10]; Chelex resin (Bio-Rad, Marnes-la-Coquette,
France).
cQiaAmp DNA minikit, Blood, tissue or nonspeciﬁed (Qiagen, Courtaboeuf,
France); Genereleaser (Bioventures Inc., ATGC Biotechnologie, Croissy-Beau-
bourg, France); MasterPure DNA puriﬁcation (Epicentre, Tebu-Bio, Le Perray-
en-Yvelines, France); HighPure PCR template preparation kit (Roche, Meylan,
France) Two methods are automated: Magnapure (Roche) and QbioRobot (Qia-
gen).
dThe sums do not account for the total because one centre used both a labora-
tory-developed method (Tween-Nonidet-NaOH) and a commercial kit (Qiagen).
Similarly, the sum of the numbers of centres using ‘conventional’ PCR (cnPCR)
and quantitative ‘real-time’ PCR (qrtPCR) does not account for the total,
because one or two centres used both technologies.
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overlap, in both targets, which renders even more question-
able any interest in this diversity. The percentage of primer
pairs that were used by only one laboratory among the par-
ticipants was high, in the range 33–58% during the study.
This proportion rises to 50–73% when considering primers
used by up to two laboratories only. Two factors should
have reduced this diversity in the transition period that this
study reﬂected, although they did not. (i) During the change
from cnPCR to qrtPCR, only a few new primer sets were
reported and could have been chosen because they appeared
highly efﬁcient in amplifying the smaller products required
for qrtPCR [7,14,21]. Still, six laboratories out of 13 kept
using the same primer set when realizing this change. (ii)
This was particularly true for the DNA target rep529 [12]
that was introduced during this period, which could have
reduced the number of primers used. By contrast, several
laboratories developed their own primer pair for this target,
perhaps as a result of the publication of nucleotide variations
TABLE 3. Diversity and evolution of DNA targets and primer sets used for the molecular PND of congenital toxoplasmosis in
France (2002–2005)a
2002 2003 2004 2005
Bl geneb 22 (19c) 21 (19) 17 (14c) 20 (15c)
cnPCR 19 (17) 14 (12) 11 (9) 7 (6)
qrtPCR 3 (3) 7 (7) 6 (6) 13 (10)
Burg et al., 1989[11] cnPCR 4 (3) 3 (2) 3 (2) 3 (2)
Bretagne et al., 1993[18] 8 (8) 8 (8) 6 (6) 8 (7)
cnPCR 8 (8) 8 (8) 6 (6) 4 (4)
qrtPCR 0 0 0 4 (3)
Foudrinier et al., 1996[20] 1 (1) 0 0 1 (1)
cnPCR 1 (1) 0 0 0
qrtPCR 0 0 0 1 (1)
Pelloux et al., 1996[22] cnPCR 2 (2) 1 (1) 1 (1) 1 (1)
Robert et al., 1996[23] cnPCR 3 (3) 2 (2) 1 (1) 1 (1)
Costa et al., 2000[19] qrtPCR 1 (1) 4 (4) 3 (3) 3 (3)
Lin et al., 2000[20] qrtPCR 1 (1) 2 (2) 2 (2) 2 (2)
Morin and Miegeville,
unpublished
cnPCR 1 (1) 0 0 0
Unpub 1 qrtPCR 1 (1) 1 (1) 1 (1) 1 (1)
rep529 1 (1) 5 (5) 12 (12) 13 (12c)
cnPCR 1 (1) 3 (3) 3 (3) 2 (2)
qrtPCR 0 2 (2) 9 (9) 11 (11)
Homan et al., 2000[12] 1 (1) 3 (3) 3 (3) 2 (2)
cnPCR 1 (1) 3 (3) 2 (2) 1 (1)
qrtPCR 0 0 1 (1) 1 (1)
Reischl et al., 2003[14] 0 1 (1) 6 (6) 6 (6)
cnPCR 0 1 (1) 1 (1) 10)
qrtPCR 0 0 5 (5) 5 (5)
Cassaing et al.,2006[13] qrtPCR 0 1 (1) 2 (2) 2 (2)
Fekkar et al., 2008[24] qrtPCR 0 0 0 1 (1)
Unpub 2 qrtPCR 0 0 1 (1) 1 (1)
Unpub 3 qrtPCR 0 0 0 1 (1)
rDNA
Cazenave et al., 1993[15] 4 (3c) 3 (3) 2 (2) 2 (2)
cnPCR 3 (3) 2 (2) 2 (2) 1 (1)
qrtPCR 1 (1) 1 (1) 0 1 (1)
TGR1E
Cristina et al., 1992[17] cnPCR 1 (1) 0 0 0
Total 28 (21c) 29 (22c) 31 (23c) 35 (25c)
cnPCR 24 (19) 19 (15) 16 (12) 10 (8)
qrtPCR 4 (4) 10 (8) 15 (13) 25 (19)
aIn the whole table, the number of methods is in clear and the number of centres that use that particular method is between brackets. For example, in 2002, 22 diagnostic
methods in 19 centres were based upon the Bl gene, overall using nine different primer pairs (listed with their bibliographic references in the far-left column, under the DNA
target).
bBl gene: 35-copy number repetitive gene (GenBank Accession N AF179871) from Burg et al. [11]; rep529: 200-300 fold repeated 529-bp non-coding element identiﬁed by
Homan et al. [12] (GenBank AccessionN AF146527) and Reishl et al.[14] (GenBank Accession N AF487550); rDNA: ribosomal DNA; TGR1E: a member of a family of
repeated DNA elements in T. gondii described by Cristina et al. [16].
cThe sums do not make the total as several centres used two or three different primer pairs. Similarly, the sum of numbers of centres using cnPCR and qrtPCR does not
make the total, as one to two centres used both technologies.
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TABLE 4. Diversity and evolution of certain good PCR practices used for the molecular prenatal diagnosis of congenital toxo-
plasmosis in Francea
2002 2003 2004 2005
Number of reaction tubes
One tube 3 2 0 0
cnPCR 3 1 0 0
qrtPCR 0 1 0 0
Two tubes 13b 11 12 10
cnPCR 11 8 4 1
qrtPCR 4 3 8 9
Three to six tubes 5 9b 11b 15b
cnPCR 5 6 7 7
qrtPCR 0 4 6 10
Extraction controlc
Plasmid 0 1 1b 0
cnPCR 0 1 1 0
qrtPCR 0 0 1 0
Toxoplasma 5d 4bd 6bd 8bd
cnPCR 5 4 4 3
qrtPCR 0 1 3 7
Duplicate 2d 3d 2d 2d
cnPCR 1 2 0 0
qrtPCR 1 1 2 2
OD 2d 3 3 4
cnPCR 2 2 1 1
qrtPCR 0 1 2 3
b-globin 3 4 4 5
cnPCR 3 3 2 2
qrtPCR 0 1 2 3
Albumin 2bd 2 2 1
cnPCR 1 0 0 0
qrtPCR 2 2 2 1
No control 9b 6 6 6
cnPCR 9 4 1 1
qrtPCR 1 2 5 5
Negative control
Yes 17b 21b 22b 25b
cnPCR 16 16 13 9
qrtPCR 3 6 11 18
No 1 1 1 0
cnPCR 0 0 0 0
qrtPCR 1 1 1 0
NSe 3 0 0 0
cnPCR 3 0 0 0
qrtPCR 0 0 0 0
Inhibition controlf
Plasmid 6b 8b 6b 5bg
cnPCR 6 8 5 3
qrtPCR 1 2 3 3
Toxoplasma 3 5 8 9g
cnPCR 3 5 5 3
qrtPCR 0 0 3 6
Human gene 4b 4 2 2
cnPCR 4 1 0 0
qrtPCR 1 3 2 2
Exogenous DNA 3 3 4 5
cnPCR 2 1 2 2
qrtPCR 1 2 2 3
No control 2 1 1 2
cnPCR 2 0 0 0
qrtPCR 0 1 1 2
NSe 3b 1 2 3
cnPCR 3 1 0 1
qrtPCR 1 0 2 2
Total 21b 22b 23b 25b
cnPCR 19 15 11 8
qrtPCR 4 8 14 19
aAll numbers here represent centres; the same information applied speciﬁcally to methods may either be not meaningful or sometimes be lacking as a result of insufﬁciently
detailed questionnaires.
bThe total does not account for the sum of the numbers below it because one or two centres used both ‘conventional’ PCR (cnPCR) and quantitative ‘real-time’ PCR
(qrtPCR).
cDNA extraction control. Plasmid: PCR ampliﬁcation after extraction of a plasmid added to the raw amniotic ﬂuid sample. Toxoplasma: concomitant extraction of a Toxo-
plasma gondii suspension in parallel to that of the sample. Optical density (OD): extracted DNA quantitation by spectrophotometric measure of the absorbance at 260 nm.
b-globin and albumin: ampliﬁcation of the corresponding human genes.
dSome laboratories used two different types of extraction controls.
eNS, not speciﬁed
fTypes of inhibition control: for details, see text.
gOne laboratory used two different types of inhibition control.
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between both reported sequences of this repetitive element
[14]. The primer diversity probably is the greatest obstacle
to standardization. Indeed, once a diagnostic assay has been
set up for routine diagnosis using a certain primer pair, difﬁ-
culties are usually experienced with respective to changing
primers in view of the workload that such a change may
imply. Our data show that most centres hesitate in making
this change (not shown). Hence, comparative studies of pri-
mer pairs become a priority in this ﬁeld. We believe that
these should be ‘intra-laboratory’ comparisons of ﬁnely ‘opti-
mized’ assays: indeed, ‘inter-laboratory’ comparative studies
are useful for assessing PCR practices and method perfor-
mances [5,6,25,26], but they do not allow conclusions to be
drawn regarding the superiority of a given method/primer
set whose value in a given application greatly depends upon
‘optimization’ and technical proﬁciency [27,28].
Similarly, an ‘intra-laboratory’ comparison may not inform
about the real respective value of the assays if both have not
been ﬁnely ‘optimized’.
Good practices for molecular diagnosis
The adaptation to routine diagnosis that follows the setting
up and ‘optimization’ of a PCR assay should include a num-
ber of good general practices [27]. We enquired about some
of these, more speciﬁcally the number of PCR reaction tubes
used for each one patient in routine diagnosis and the use of
controls (veriﬁcation of DNA extraction, negative and posi-
tive controls), all of which also appeared highly diverse
(Table 4; see also Supporting Information, Data S3).
Conclusion
This 4-year survey allows a detailed and almost comprehen-
sive description of the practices in the molecular diagnosis of
congenital toxoplasmosis in a country which attributes a con-
siderable medical importance to this infection. The observed
diversity is considerable, essentially because of the use of
independent laboratory-developed methods. No consensus
exists for any step of the whole process, be it DNA extrac-
tion, DNA target/primers, or detection methods; further-
more, there is no sign that this diversity should decrease.
There were as many extraction methods in 2005 as there
were in 2002, and the introduction of automated extraction
may further increase this diversity. Similarly, there were
almost as many primers sets used for rep529 in 2005 than
for the B1 gene in 2002.
This diversity in itself constitutes an obstacle to the stan-
dardization of diagnostic methods as well as to the compara-
bility of results among different laboratories. The question of
a correlation between any method and its results and perfor-
mance (i.e. whether some methods proved to be more efﬁ-
cient than others during the various external quality
assessments) [8] cannot be answered here, perhaps precisely
because of this diversity. Our experience, as well as that of
different groups [5,6,26,29], demonstrate that no link can be
made between the methods and the results of comparative
assessment studies. This points out the crucial importance of
proﬁciency and optimization of PCR conditions, rather than
the method itself, for establishing a solid molecular diagnosis.
Thus, the great range of sensitivities of PND observed in a
recent multicentric European study [30] may reﬂect the dif-
ferent performances of the methods, varying proﬁciency
among centres, or true differences in the pathology. In turn,
this issue prevents CT control policies from being efﬁciently
evaluated. Moreover, the molecular PND of CT suffers from
a relatively high rate of false negative results, approximately
30% (mean) in Europe [30] and in the range 10–35% in
France [30–32]; it appears that this rate cannot be reduced
to zero, probably essentially for physiopathological reasons,
such as delayed transplacental transmission or the high fre-
quency of low parasite loads in amniotic ﬂuid [7]. This
implies that the molecular diagnostic method must be highly
sensitive. Given that the diversity of methods and practices
observed in the present study is far from decreasing, it
appears that, rather than to standardize the existing meth-
ods, it better assess their performances would be more
practical to, using a common and calibrated basic material.
This may be achieved through an external quality assessment
that would not only aim to verify that the laboratories are
able to detect positive samples and to return negative
samples as negative, such as those existing in France and in
Europe [6,8], but also would allow an estimation of the
sensitivity thresholds of their methods.
During the present study, annual reports were sent to the
participants, including recommendations drawn from the anal-
ysis of both the external quality assessment results [8] and the
accompanying questionnaires, with a view to improving labora-
tory practices for CT diagnosis at the national level. Without
knowing whether this is the fruit of technical and proﬁciency
evolution or the consequences of these recommendations, we
observed an improvement of certain practices over the years:
in particular, evolution toward abandoning less efﬁcient DNA
targets (i.e. TGR1E and rDNA) and generalization of certain
good practices. For example, (i) the proportion of laboratories
that did not verify their DNA extraction decreased from 45%
to 24%; (ii) all centres included negative controls in 2005; (iii)
the median of the number of reaction tubes per biological sam-
ple increased from two to three and all laboratories have been
using more than one tube subsequent to 2004. By contrast,
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the number of centres that do not use any inhibition control
remained stable at approximately 12%. The objective here
should be that any laboratory involved in PND of CT should
include inhibition controls. In summary, we strongly consider
that such surveys, accompanying the assessment of the perfor-
mances of PND methods and practices (which is a major
objective of the French National Centre for Toxoplasmosis),
should be performed wherever a routine diagnosis of CT is
made.
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